This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-06 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== Discovery == Apelin is a peptide hormone that was identified in 1998 by Masahiko Fujino and his colleagues at Gunma University and Takeda Pharmaceutical Company. In 2013, a second peptide hormone named Elabela was found by Bruno Reversade to also act as an endogenous ligand to the APLNR.
In the early nineteenth century, it was still undecided which port would be chosen as the primary sea link along the route from London to Dublin: Porthdinllaen, on the Llŷn Peninsula, or Holyhead in Anglesey. In May 1806, the Porthdinlleyn Harbour Act 1806 (46 Geo. 3. c. xxxiv) approved new buildings in Porthdinllaen when it seemed that the town would be chosen. Porthdinllaen was almost as far west as Holyhead, but Holyhead was more accessible because of Thomas Telford's road developments. Porthdinllaen Harbour Company was formed in 1808 in preparation, but the bill before Parliament to constitute Porthdinllaen as a harbour for Irish trade was rejected in 1810. Holyhead's maritime importance was at its height in the 19th century with a 1+3⁄4-mile-long (2.8-kilometre) sea breakwater. Holyhead Breakwater, built to create a safe harbour for vessels caught in stormy waters on their way to Liverpool and the industrial ports of Lancashire; it is the longest breakwater in the UK. Throughout the later 18th century and the entire 19th century, Holyhead was a crucial transit point for landed gentry and British parliamentarians and military officials who were travelling from Ireland to London. It was also a transit point for British owners of multinational estates visiting their 'other lands' or London houses. The port of Holyhead saw significant development throughout the 19th century to accommodate the growing passenger traffic between Holyhead and Dublin, which reached approximately 14,000 passengers annually by 1814.
== Adverse effects == Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides. Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils. Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.
On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:
== Bibliography == Brown, M.S, Engelking, L.J, Evers, B, Goldstein, J.L, Hammer, R.E, Horton, J.D, Kuriyama, H, Liang, G, Li, W.P, & Liang, G 2005, 'Schoenheimer effect explained - Feedback regulation of cholesterol synthesis in mice mediated by Insig proteins', The Journal of clinical investigation, vol. 115, pp. 2489–98 Clarke, Hans T (12 December 1941). "Rudolf Schoenheimer, 1898-1941". Science, New Series. 94: 553–554. Cooper, D.Y, & Osborn, M.E 1999, 'Schoenheimer, Rudolph', American National Biography Helmenstine, A.M 2019, 'Deuterium Facts', https://www.thoughtco.com/facts-about-deuterium-607910 Engelking, L. J. (2005-08-25). "Schoenheimer effect explained - feedback regulation of cholesterol synthesis in mice mediated by Insig proteins". Journal of Clinical Investigation. 115 (9): 2489–2498. doi:10.1172/jci25614 ISSN 0021-9738. Fruton, Joseph S. (January 1982). "The carbobenzoxy method of peptide synthesis". Trends in Biochemical Sciences. 7 (1): 37–39. doi:10.1016/0968-0004(82)90064-0 ISSN 0968-0004. Hargrove, James L. (1998). Dynamic modeling in the health sciences. Springer. pp. ix. ISBN 0-387-94996-8. OCLC 876222114 Helmenstine, A.M (2019). "Deuterium Facts". Kohler R, Jr 1977, 'Rudolph Schoenheimer, Isotopic Tracers, and Biochemistry in the 1930s', Historical Studies in the Physical Sciences, vol. 8, pp. 257–298 Medawar, Jean: Pyke, David (2012). Hitler's Gift: The True Story of the Scientists Expelled by the Nazi Regime (Paperback). New York: Arcade Publishing. ISBN 978-1-61145-709-4.{{cite book}}: CS1 maint: multiple names: authors list (link) Quastel J.H.
Sources: en.wikipedia.org
Germany, the birthplace of decaffeinated coffee, is home to several decaffeination plants, including the world's largest, Coffein Compagnie. Over half of the decaf coffee sold in the US first travels from the tropics to Germany for caffeine removal before making its way to American consumers. Coffee manufacturers recover the caffeine and resell it for use in soft drinks and over-the-counter caffeine tablets. The efficiency and selectivity of caffeine removal depend on the decaffeination method used. Water-based processes and supercritical carbon dioxide extraction are generally more selective, as they remove caffeine while preserving a larger proportion of volatile flavor compounds compared to some organic solvent methods. Extraction of caffeine from coffee, to produce caffeine and decaffeinated coffee, can be performed using various solvents. Following are main methods:
For example, in one 6-week study, the median time to achieving consistent response was 29 days. Likewise, complete excretion of the drug may take several weeks. During the first week after treatment discontinuation, the brain concentration of fluoxetine decreases by only 50%, The blood level of norfluoxetine four weeks after treatment discontinuation is about 80% of the level registered by the end of the first treatment week, and, seven weeks after discontinuation, norfluoxetine is still detectable in the blood.
Yeast extracts consist of the cell contents of yeast without the cell walls; they are used as food additives or flavorings, or as nutrients for bacterial culture media. They are often used to create savoury flavors and umami taste sensations and can be found in a large variety of packaged foods including frozen meals, crackers, snack foods, gravy, stock and more. They are rich in B vitamins (but not B12). Yeast extracts and fermented foods contain glutamic acid (free glutamates), an amino acid which adds an umami flavor. Glutamic acid is found in meat, cheese, fungi (mushrooms and yeast) and vegetables—such as broccoli and tomatoes. A number of other substances found in yeast extract provide aromas, some meat-like, when allowed to react under heat. The thermal process to make yeast extract of the autolysate type was invented in the 19th century by Justus von Liebig. Yeast cells are heated until they rupture, then the cells' own digestive enzymes combined with the intense heat help to break large proteins down into simpler compounds (amino acids and peptides), a process called autolysis. The insoluble cell walls are then separated by centrifuge, filtered, and usually spray-dried. This is the process used for spreads such as Vegemite and Marmite. Yeast extracts in liquid form can be dried to a light paste or a dry powder. This is not the same as nutritional yeast seasonings, which are made from lyophilized intact cells and consequently have a lighter flavor.
President Wee Kim Wee accepted her plea for clemency in 1992 and her death sentence was commuted to life imprisonment; her two accomplices, however, were executed in 1992. While serving her life sentence, she was diagnosed with cervical cancer in 1993 and had at most a year to live. She appealed to President Ong Teng Cheong for clemency so that she could be released in order to spend the final moments of her life with her family. The president accepted the petition, and she was released on 16 February 1995 and eventually died on 30 March that year. 1992: Koh Swee Beng, a Singaporean who killed a man who assaulted his foster father in 1988. He was convicted of murder and sentenced to hang in 1990. He lost his appeal against his death sentence in 1991 but was eventually granted clemency by President Wee Kim Wee on 13 May 1992 (two days before he was scheduled to be executed) and had his sentence commuted to life imprisonment. He was released from prison in September 2005 for good behaviour after serving at least two-thirds of his life sentence. 1998: Mathavakannan Kalimuthu, a Singaporean convicted of murder and sentenced to hang in 1996 along with his two friends. After losing their appeals in 1997, the three of them petitioned to President Ong Teng Cheong for clemency in 1998. The president accepted only Mathavakannan's plea so his sentence was commuted to life imprisonment; the other two had their pleas rejected and were subsequently executed. Mathavakannan was eventually released in 2012 after spending about 16 years in prison.
The Asmara College of Health Sciences is a public college in Asmara, Eritrea. It was founded in 1999 (1999) as one of the faculties at the University of Asmara with the aim of creating competent health professionals to meet the health needs of the nation. The college acquired its present independent status in 2005. The college has five major branches, namely: the School of Allied Health Professions, the School of Nursing, the School of Pharmacy, the School of Public Health, and the Department of Basic and Behavioral Sciences. The college offers BSc degrees in nursing, public health, pharmacy, ophthalmology, midwifery, and clinical laboratory sciences. It also trains technicians to diploma level in pharmacy, dentistry, physiotheraphy, radiology, and laboratory research. Since the college was founded, 3145 students have graduated, of whom 45% are female.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.